Preventative CMV Vaccine showed positive results in Phase I study

| By | Clinical Trials, Development of Vaccines
0
126

VBI Vaccines announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate.

VBI-1501 was developed using the company’s proprietary enveloped virus-like particle (eVLP) technology and presents a modified form of the glycoprotein B (gB) found on CMV. The final Phase 1 study results demonstrated that VBI-1501 was safe and well-tolerated at all doses.

VBI Vaccines is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac® is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma (GBM).

VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

SOURCE: vbi vaccines
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.